Lexicon Pharmaceuticals
LXRX
94 hedge funds and large institutions have $802M invested in Lexicon Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 40 closing their positions.
38% more call options, than puts
Call options by funds: $22K | Put options by funds: $16K
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
23% more capital invested
Capital invested by funds: $654M → $802M (+$148M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less funds holding
Funds holding: 119 → 94 (-25)
60% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$7.36M |
| 2 |
BM
Bridger Management
New York
|
+$1.91M |
| 3 |
TRSOTSOK
Teachers Retirement System of the State of Kentucky
Frankfort,
Kentucky
|
+$1.53M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$975K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$768K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.29M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$2.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.8M |
| 4 |
AGC
Alden Global Capital
Brandon,
Florida
|
-$851K |
| 5 |
TCT
TIAA CREF Trust
St Louis,
Missouri
|
-$760K |
LXRX Hedge Fund Activity: Q2 2015 in Review
94 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2015, worth a combined $802M — up 23% from $654M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of LXRX and 16 opened new positions — a net loss of 24 holders — while 28 trimmed existing stakes and 37 added.
The largest buyer was UBS AM, adding an estimated $7.36M. The largest seller was Sabby Management, cutting an estimated $3.29M.
- 94 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2015, down from 119 in Q1 2015.
- Funds reported $802M of Lexicon Pharmaceuticals stock for Q2 2015, up 23% quarter-over-quarter.
- 16 funds opened new Lexicon Pharmaceuticals positions in Q2 2015 and 40 closed out, a net change of -24 holders.
- The largest Lexicon Pharmaceuticals buyer in Q2 2015 was UBS AM, an estimated $7.36M added.
- The largest Lexicon Pharmaceuticals seller in Q2 2015 was Sabby Management, an estimated $3.29M sold.
Based on aggregated 13F filings for Q2 2015.